Feature Review,FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List

The classification of peptides by the FDA has been a dynamic and often debated topic, particularly concerning substances placed in Category 2. This designation signifies that the FDA has identified potential significant safety risks associated with these bulk drug substances, impacting their availability for compounding. Understanding the nuances of peptides Category 2 FDA regulations is crucial for healthcare providers, compounding pharmacies, and patients seeking specific therapeutic options.

In late 2023, a significant shift occurred when the FDA placed 19 commonly used peptides into Category 2. This move effectively prevented compounding pharmacies from using these peptides under the 503A compounding framework. Some of the substances that were placed on this list include well-known compounds like BPC-157, Thymosin Alpha-1 (TA-1), CJC-1295, Ipamorelin, and Selank Nasal. The rationale behind this action, as stated by the agency, was the identification of significant safety risks associated with these specific peptides. This led to widespread discussion and concern within the medical and pharmaceutical communities.

However, the regulatory landscape surrounding peptides Category 2 is not static. The FDA has been actively reviewing these classifications, leading to subsequent updates. For instance, in October 2024, the FDA removed five peptide bulk drug substances from Category 2. These included Thymosin Alpha-1 (TA-1), CJC-1295, Ipamorelin, Pentadecapeptide, and Selank Nasal. This removal indicates a reassessment of the safety profiles of these particular peptides or a change in the agency's approach to their regulation.

Furthermore, there have been indications of further reclassifications. Reports suggest that the FDA is expected to lift restrictions on certain peptides, with some sources indicating that 12 popular peptides may be removed from the Category 2 "Do Not Compound" list by April 2026. This potential shift is significant, as it could restore access to these peptides for compounding purposes.

The classification process itself is complex. A bulk drug substance that the FDA identifies as presenting a potential significant safety risk might not appear in Category 2 if insufficient information is provided for evaluation. Conversely, substances in Category 2 were nominated with sufficient supporting information to permit the FDA to evaluate them, and they may be eligible for further consideration.

It's important to note that the FDA's actions have sometimes been met with legal challenges and strong opinions. For example, there have been claims that the FDA “illegally” moved the peptides to a Category 2 designation during the Biden administration. These assertions highlight the contentious nature of the regulatory decisions and the differing interpretations of the FDA's authority and actions.

While the focus has often been on the restrictions, it's also pertinent to understand the broader framework. The FDA's interim policy guidance and updates regarding bulk drug substances are central to these decisions. Understanding what Category 1 and Category 2 mean within the FDA's compounding framework is essential. Category 2 substances are those identified with potential significant safety risks, while Category 1 substances are typically those that meet certain criteria for use in compounding.

The evolving status of peptides within the FDA's regulatory system, particularly concerning Category 2, underscores the need for continuous monitoring of FDA announcements and regulatory updates. For professionals and patients alike, staying informed about these changes is vital for making informed decisions regarding therapeutic options. The FDA's role in ensuring the safety and efficacy of drug substances remains paramount, and the ongoing reevaluation of peptides reflects this commitment.